Titan Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>TP</div>
TTNP -- USA Stock  

USD 3.50  0.14  3.85%

Titan Pharmaceuticals Market Capitalization is very stable at the moment as compared to the past year. Titan Pharmaceuticals reported last year Market Capitalization of 102.42 Million. As of 13th of November 2020, Tangible Asset Value is likely to grow to about 15.7 M, while Free Cash Flow is likely to drop (7.4 M). There are many examples of share prices declining after an abrupt shift in one of the basic indicators. Let's recap some of Titan Pharmaceuticals' important ratios. We will evaluate why recent Titan Pharmaceuticals price moves suggest a bounce in December. Will insiders continue to hold, or should we expect a sell-off?
Published over two weeks ago
View all stories for Titan Pharmaceuticals | View All Stories
Are Titan Pharmaceuticals (NASDAQ:TTNP) unfluctuating basic indicators contributing to the recent decline?
Titan Pharmaceuticals is UNDERVALUED at 0.29 per share with modest projections ahead. Titan Pharmaceuticals owns Efficiency Ratio (i.e. Sharpe Ratio) of -0.1, which indicates the firm had -0.1% of return per unit of risk over the last month. Macroaxis standpoint towards measuring the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Titan Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to validate Titan Pharmaceuticals risk adjusted performance of (0.13), and Coefficient Of Variation of (887.72) to confirm the risk estimate we provide.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Titan Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Potential Titan Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Titan Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Titan Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Titan Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Titan Pharmaceuticals fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Titan Pharmaceuticals performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Titan Pharmaceuticals shares is the value that is considered the true value of the share. If the intrinsic value Titan is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Titan Pharmaceuticals. Please read more on our fundamental analysis page.

How important is Titan Pharmaceuticals's Liquidity

Titan Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Titan Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Titan Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Titan Pharmaceuticals's total debt and its cash.

How Titan utilizes its cash?

To perform a cash flow analysis of Titan Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Titan Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Titan Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Titan Pharmaceuticals Net Cash Flow from Operations is very stable at the moment as compared to the past year. Titan Pharmaceuticals reported last year Net Cash Flow from Operations of 5.66 Million

Titan Pharmaceuticals Gross Profit

Titan Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Titan Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Titan Pharmaceuticals Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Breaking it down a bit more

The big decline in price over the last few months for Titan Pharmaceuticals created some momentum for insiders as it was traded today as low as 0.11 and as high as 0.12 per share. The company executives failed to add value to investors and positioning the company supply of money to exploit market volatility in October. However, diversifying your holdings with Titan Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 8.93. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Titan Pharmaceuticals partners.
 2019 2020 (projected)
Interest Expense1.8 M1.85 M
Gross Profit1.5 M2.05 M

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Titan Pharmaceuticals has an asset utilization ratio of 36.35 percent. This suggests that the company is making $0.36 for each dollar of assets. An increasing asset utilization means that Titan Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
14.7 M
Current Assets14.74 Million92.84
Assets Non Current1.14 Million7.16

Our take on Titan Pharmaceuticals to recoup

Recent standard deviation is at 8.89. As of the 13th of November 2020, Titan Pharmaceuticals has the coefficient of variation of (887.72), and Risk Adjusted Performance of (0.13). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Titan Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Titan Pharmaceuticals, which can be compared to its competition. Please validate Titan Pharmaceuticals jensen alpha and semi variance to decide if Titan Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 0.12 per share. As Titan Pharmaceuticals appears to be a penny stock we also recommend to double-check its total risk alpha numbers.

The Current Takeaway on Titan Pharmaceuticals Investment

Although some firms in the biotechnology industry are either recovering or due for a correction, Titan Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 13th of November 2020, we believe that Titan Pharmaceuticals is currently undervalued with significantly high odds of financial distress in the next two years. However, our latest 30 days 'Buy-Sell' recommendation on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Titan Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com